Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07097480
Recruiting Not applicable

Virus Transmission to People Recently Bitten or With a History of Monkey Bites "SIMVIR

NCT07097480 · tracked via the Priya Life Science France tracker
Sponsor
Institut Pasteur
Phase
Not applicable
Started
2025-08-14
Last updated
2025-12-15

Condition(s) studied

Bites Monkey

Investigational drug(s) / intervention(s)

Blood samples collectionSaliva samples collection

Blood samples collection: Blood samples of 40 ml will be taken.

Saliva samples collection: Saliva samples will be collected

Study summary

Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.

The objective of the study is to investigate the prevalence of STLV-1 and SFV infections following a nonhuman primate bite.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Bite inflicted by an HNP (WHO category 3 level) * Written informed consent * Affiliation with a social security scheme (excluding State Medical Aid Specific criteria for genetic analyses: * Participant has checked the boxes for participation in the genetic component. Exclusion Criteria: * Patient presenting only with scratches inflicted by a PNH * Medical management incompatible with the objectives of the study * Patient who, in the doctor's opinion, is unlikely to comply with the study protocol * Health conditions are incompatible with the sample collection required by the study * Patient under legal protection (guardianship or trusteeship)

Primary outcome measure(s)

  • Study the prevalence of STLV-1 and SFV infections following an NHP bite. — 17 months
    Detection of specific antibodies and viral DNA against both viruses in blood.

Trial sites (1)

FacilityCityRegionStatus
Institut Pasteur Medical Center Paris France Recruiting

More Institut Pasteur trials in France

Development of a Battery of Audiological Tests for the Precision Diagnosis of Age-related Hearing Loss Recruiting
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis Recruiting
Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia Starting soon
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Recruiting
Description of the Immune Response to Yellow Fever Vaccination Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07097480 on ClinicalTrials.gov ↗ ← All trials in France